WIXOM, Mich. , June 1, 2022
/PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a
biopharmaceutical company dedicated to transforming the treatment
of iron deficiency and anemia management, today announced that it
received notice from The NASDAQ Stock Market LLC (NASDAQ) on
May 31, 2022 informing Rockwell
Medical that it has regained compliance with the minimum bid price
requirement under NASDAQ Listing Rule 5550(a)(2) for continued
listing on The NASDAQ Capital Market. Consequently, Rockwell is now
in compliance with all applicable listing standards and its common
stock will continue to be listed on The NASDAQ Capital Market.
Rockwell Medical was previously notified by NASDAQ on
June 11, 2021 that it was not in
compliance with the minimum bid price rule because its common stock
failed to meet the closing bid price of $1.00 or more for 30 consecutive business days.
To regain compliance with the minimum bid price rule, the Company
was required to maintain a minimum closing bid price of
$1.00 or more for at least 10
consecutive trading days. This requirement was met on May 27, 2022, the eleventh consecutive trading
day when the closing bid price of the Company's common stock was
over $1.00.
About Rockwell Medical
Rockwell Medical is a commercial-stage biopharmaceutical
company developing and commercializing its next-generation
parenteral iron technology platform, Ferric Pyrophosphate Citrate
(FPC), which has the potential to lead transformative treatments
for iron deficiency in multiple disease states, reduce healthcare
costs and improve patients' lives. The Company has two FDA-approved
therapies indicated for patients undergoing hemodialysis, which are
the first two products developed from the FPC
platform. Rockwell Medical is also advancing its FPC
platform by developing FPC for the treatment of iron deficiency
anemia in patients outside of dialysis, who are receiving
intravenous medications in the home infusion setting. In
addition, Rockwell Medical is one of two major suppliers
of life-saving hemodialysis concentrate products to kidney dialysis
clinics in the United States.
For more information, visit www.RockwellMed.com.
Forward-Looking
Statements
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as, "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue," "could,"
"can," "would," "develop," "plan," "potential," "predict,"
"forecast," "project," "intend," "look forward to," "remain
confident" or the negative of these terms, and similar expressions,
or statements regarding intent, belief, or current expectations,
are forward looking statements. While Rockwell Medical believes
these forward-looking statements are reasonable, undue reliance
should not be placed on any such forward-looking statements, which
are based on information available to us on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties (including, without limitation, those set forth in
Rockwell Medical's SEC filings), many of which are beyond our
control and subject to change. Actual results could be materially
different. Risks and uncertainties include, but are not limited to
those risks more fully discussed in the "Risk Factors" section of
our Annual Report on Form 10-K for the year ended December 31, 2021, as such description may be
amended or updated in any future reports we file with the SEC.
Rockwell Medical expressly disclaims any obligation to update our
forward-looking statements, except as may be required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rockwell-medical-regains-compliance-with-nasdaq-listing-requirements-301558542.html
SOURCE Rockwell Medical Technologies, Inc.